24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

7579 General Poster Session (Board #49E), Sat, 1:15 PM-5:15 PM<br />

Family history <strong>of</strong> lung cancer in never smokers with non-small cell lung<br />

cancer (NSCLC) and its association with tumors harboring epidermal<br />

growth factor receptor (EGFR) mutations. Presenting Author: Elizabeth<br />

Mary Gaughan, Beth Israel Deaconess Medical Center/Harvard Medical<br />

School, Boston, MA<br />

Background: Inherited susceptibility to lung cancer is an understudied<br />

subject, however it has been described among never smokers (�100<br />

cigarettes/lifetime). Never smokers with NSCLC comprise an important<br />

subgroup <strong>of</strong> patients enriched for tumors harboring oncogene aberrations in<br />

the EGFR and ALK genes. We aimed to better characterize the incidence <strong>of</strong><br />

family history <strong>of</strong> lung cancer in the setting <strong>of</strong> routine tumor genotyping<br />

among never smokers with NSCLC. Methods: Clinicopathologic data plus<br />

tumor genotype (EGFR, KRAS, ALK) from 230 consecutive never smokers<br />

seen at Beth Israel Deaconess Medical Center and Dana-Farber Cancer<br />

Institute was compiled. We retrospectively analyzed the incidence <strong>of</strong> a<br />

family history <strong>of</strong> any cancer and lung cancer in these patients. Results: In<br />

our cohort, the average age was 56 years, 67% <strong>of</strong> the patients were women,<br />

75% were white, 41% had advanced NSCLC and 87% had adenocarcinoma<br />

histology. In these tumors, 98/230 (43%) had an EGFR mutation,<br />

16/155 (10%) had KRAS mutations and 27/127 (17%) had an ALK<br />

translocation. Family history <strong>of</strong> any cancer was common (57%) and specific<br />

family history <strong>of</strong> lung cancer was present in 42/230 cases (18%). Out <strong>of</strong><br />

thecases with a family history <strong>of</strong> any cancer, 22/53 (41.5%) EGFRmutated,<br />

1/6 (17%) KRAS-mutated and 3/20 (15%) ALK-translocated<br />

cohorts had a family history <strong>of</strong> lung cancer. The rate <strong>of</strong> family history <strong>of</strong> lung<br />

cancer to family history <strong>of</strong> cancer was significantly higher in the EGFRmutated<br />

cohort when compared to the ALK translocated plus KRASmutated<br />

cohorts (p�0.023). Conclusions: Family history <strong>of</strong> lung cancer is<br />

common in never smokers with NSCLC, and there seems to be a particular<br />

link in families in which the proband has an EGFR-mutated tumor. Further<br />

study <strong>of</strong> families with EGFR-mutated NSCLC may yield insights into the<br />

pathogenesis <strong>of</strong> this tumor type.<br />

7581 General Poster Session (Board #49G), Sat, 1:15 PM-5:15 PM<br />

NGR-hTNF plus chemotherapy as first-line therapy <strong>of</strong> non-small cell lung<br />

cancer (NSCLC). Presenting Author: Vanesa Gregorc, Department <strong>of</strong><br />

Oncology, Istituto Scientifico San Raffaele, Milan, Italy<br />

Background: NGR-hTNF (asparagine-glycine-arginine human tumor necrosis<br />

factor) is a selective vascular targeting agent able to improve intratumoral<br />

chemotherapy uptake. Methods: Chemo-naive, stage IIIb-IV NSCLC<br />

patients (pts), stratified by histology (nonsquamous or squamous) and PS<br />

(0 or 1), were randomized to cisplatin 80 mg/m2 /day(d)1 plus either<br />

pemetrexed 500 mg/m2 /d1 (nonsquamous) or gemcitabine 1,250 mg/m2 /<br />

d1�8 (squamous) every 3 weeks (q3w) up to 6 cycles with (arm A) or<br />

without (arm B) NGR-hTNF 0.8 �g/m2 /d1 q3w until progression. Progression<br />

free survival (PFS) was primary end point <strong>of</strong> this phase 2 trial<br />

(��20%, ��20%, HR�0.62, and n�102). Secondary end points included<br />

adverse events (AEs), response rate (RR) and overall survival (OS).<br />

Results: 59 pts were assigned to arm A and 57 to arm B. Baseline<br />

characteristics in arm A/B were: median age 62/63; male 34/37; PS 1<br />

21/21; squamous 15/15; nonsmokers 14/12; EGFR mutations 5/5. For the<br />

nonsquamous group, 281 cycles (mean 6.5; range 1-18) were given in arm<br />

A and 190 (mean 4.7; range 1-6) in arm B, while for the squamous group,<br />

88 (mean 6.3; range 1-19) in arm A and 48 (mean 3.7; range 1-6) in arm<br />

B. Most common grade 3/4 AEs were neutropenia 14% vs 17% and fatigue<br />

7% vs 11% in arm A and B, respectively. No grade 3/4 AEs related to<br />

NGR-hTNF or bleeding in pts with squamous histology were noted. Median<br />

follow-up was 12.4 months. In the whole study population, median (m)PFS<br />

was 5.8 vs 5.7 months (HR�0.95), RR was 23% vs 19%, and 1-year OS<br />

was 62% vs 62% in arm A and B, respectively. In the nonsquamous subset,<br />

a trend toward longer mPFS in arm A compared to arm B was noted in pts<br />

with a PS <strong>of</strong> 1 (6.7 vs 4.6 months, respectively), nonsmoking history (6.2 vs<br />

3.4), younger age (6.5 vs 3.4), and EGFR mutations (7.2 vs 3.3). In the<br />

squamous subset, mPFS was 5.1 vs 3.9 months (HR�0.71) and mOS was<br />

14.2 vs 10.8 months (HR�0.73) in arm A and B, respectively. In these pts,<br />

ORR was 36% in arm A and 23% in arm B, while median changes from<br />

baseline in target tumor size after 2, 4, and 6 cycles were -29%, -45%, and<br />

-41%, respectively in arm A, and -18%, -22%, and -14%, respectively in<br />

arm B. Conclusions: Regardless <strong>of</strong> histology, NGR-hTNF can be safely given<br />

with standard chemotherapy, showing tolerability and hint <strong>of</strong> activity in<br />

squamous NSCLC.<br />

Lung Cancer—Non-small Cell Metastatic<br />

499s<br />

7580 General Poster Session (Board #49F), Sat, 1:15 PM-5:15 PM<br />

Comparison <strong>of</strong> the KRAS/EGFR mutation pr<strong>of</strong>ile and survival <strong>of</strong> “collegiate<br />

smokers” and never smokers with advanced lung cancers. Presenting<br />

Author: Anna M. Varghese, Memorial Sloan-Kettering Cancer Center, New<br />

York, NY<br />

Background: In practice, we encounter patients (pts) with lung cancers who<br />

state they smoked only while in college. The impact <strong>of</strong> this degree <strong>of</strong><br />

tobacco use on cancer biology is unknown. We have shown that EGFR<br />

mutations are less common in pts who smoked � 15 pack years (PY). We<br />

hypothesize that among pts with lung cancer the KRAS / EGFR mutation<br />

pr<strong>of</strong>ile and overall survival (OS) <strong>of</strong> “collegiate smokers” (former smokers<br />

who smoked between 101 lifetime cigarettes and 5 PY) will be distinct<br />

from never smokers and former smokers with � 15 PY. Methods: We<br />

collected age, sex, stage, and survival for pts evaluated from 2004 - 2009<br />

with stage IIIB/IV lung cancer with known KRAS and EGFR status. ALK<br />

testing was not available routinely during this time. Smoking history was<br />

obtained using a patient completed survey. The Fisher exact test was used<br />

to compare mutation pr<strong>of</strong>iles. The log rank test was used to compare OS.<br />

Results: Smoking history and clinical data were available for 852 pts with<br />

Stage IIIB/IV lung cancer with known KRAS and EGFR status: 307 never<br />

smokers, 178 current smokers, and 367 former smokers. Of the former<br />

smokers, 55 were “collegiate smokers”, 61 had smoked 5-15 PY, and 251<br />

had smoked � 15 PY. The KRAS / EGFR mutation pr<strong>of</strong>iles by smoking<br />

history are shown below (Table). The KRAS / EGFR mutation pr<strong>of</strong>ile <strong>of</strong><br />

“collegiate smokers” is distinct from those <strong>of</strong> pts who were never smokers<br />

(p � .001) and former smokers with � 15 PY (p � .001) but similar to that<br />

<strong>of</strong> pts who were former smokers with 5-15 PY (p � 0.9). Median OS after<br />

diagnosis <strong>of</strong> stage IIIB/IV lung cancer for “collegiate smokers” was 25<br />

months (mos), compared to 32 mos for never smokers (p � 0.4) and 21<br />

mos for former smokers with � 15 PY (p � 0.63). Conclusions: “Collegiate<br />

smokers” are a distinct group <strong>of</strong> pts with a higher incidence <strong>of</strong> KRAS<br />

mutations and lower incidence <strong>of</strong> EGFR mutations compared to never<br />

smokers. These data suggest that even a small amount <strong>of</strong> cigarette smoking<br />

influences the biology <strong>of</strong> lung cancer. These findings reinforce the<br />

importance <strong>of</strong> doing mutation testing routinely for all pts with lung cancer<br />

to guide clinical care.<br />

Total EGFR KRAS<br />

N N % N %<br />

Never smokers 307 149 49 13 4<br />

�Collegiate smokers� 55 15 27 8 15<br />

Former smokers with > 15 pack years 251 27 11 100 40<br />

7582 General Poster Session (Board #49H), Sat, 1:15 PM-5:15 PM<br />

Thymidylate synthase (TS) gene expression in patients with ALK positive<br />

(�) non-small cell lung cancer (NSCLC): Implications for therapy. Presenting<br />

Author: David R. Gandara, University <strong>of</strong> California Davis Cancer Center,<br />

Sacramento, CA<br />

Background: ALK� NSCLC represents a molecular target-defined patient<br />

population highly responsive to the ALK inhibitor crizotinib. Previous<br />

reports have also suggested increased sensitivity <strong>of</strong> ALK� NSCLC to the<br />

chemotherapeutic agent pemetrexed. Thymidylate synthase (TS) is a<br />

candidate predictive biomarker for pemetrexed activity. Here we report<br />

analysis <strong>of</strong> the Response Genetics Inc. (RGI) database for this association<br />

and implications for therapy. Methods: ALK fusion was identified by a novel<br />

RT-PCR assay (Danenberg et al: ASCO 2010). For TS, RNA from microdissected<br />

formalin-fixed paraffin-embedded tumors was analyzed as previously<br />

described, reported as the ratio <strong>of</strong> gene expression to �-actin. For<br />

reference, a TS level �2.33 is the cutpoint for sensitivity. Results: TS levels<br />

were available from 63 ALK� patients and 1,698 ALK- control lung<br />

adenocarcinoma patients. All ALK� patients had adenocarcinomas without<br />

EGFR or KRAS mutations. Median age: 59.0 (range 33-88), gender<br />

(male/female) 32/31 (51%/49%). Median TS RNA level in ALK� patients<br />

was 2.02, range (0.55-19.44), and in ALK- patients was 3.32 (0.36-<br />

53.51), p�0.0001 (Mann-Whitney test). The majority <strong>of</strong> ALK� patients<br />

(N�43, 68%) had a TS level �2.33 cutpoint, compared to only 32% <strong>of</strong><br />

ALK- patients (N�551, p�0.0001). Conclusions: This analysis demonstrates<br />

relatively low TS gene expression in ALK� patient tumors as<br />

determined by RT-PCR. These data provide a mechanism <strong>of</strong> action<br />

supportive <strong>of</strong> pemetrexed sensitivity for ALK� NSCLC.<br />

TS expression N Median 95% CI Range Mean 95% CI p value<br />

ALK� patients 63 2.02 1.60-2.11 0.55-19.44 2.53 1.89-3.16 �0.0001<br />

ALK- patients 1698 3.32 3.15-3.45 0.36-53.51 7.87 1.68-14.05<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!